An overview of doxorubicin formulations in cancer therapy.
about
Combination of glycosphingosomes and liposomal doxorubicin shows increased activity against dimethyl-α-benzanthracene-induced fibrosarcoma in mice.Novel proteasome inhibitor ixazomib sensitizes neuroblastoma cells to doxorubicin treatment.Guiding TRAIL to cancer cells through Kv10.1 potassium channel overcomes resistance to doxorubicin.Targeted delivery of paclitaxel and doxorubicin to cancer xenografts via the nanoparticle of nano-diamino-tetrac.Decursin in Angelica gigas Nakai (AGN) Enhances Doxorubicin Chemosensitivity in NCI/ADR-RES Ovarian Cancer Cells via Inhibition of P-glycoprotein Expression.Heart failure and chemotherapeutic agents.Strategies to release doxorubicin from doxorubicin delivery vehicles.Cyclodextrin-based nanosponges: a versatile platform for cancer nanotherapeutics development.Differential toxicity of gold-doxorubicin in cancer cells vs. cardiomyocytes as measured by real-time growth assays and fluorescence lifetime imaging microscopy (FLIM).Lung cancer combination therapy: co-delivery of paclitaxel and doxorubicin by nanostructured lipid carriers for synergistic effect.(-)-Epicatechin-3-gallate (a polyphenol from green tea) potentiates doxorubicin-induced apoptosis in H9C2 cardiomyocytes.Plk1 Inhibitors in Cancer Therapy: From Laboratory to Clinics.The efficacy and safety of pegylated liposomal doxorubicin monotherapy and combination therapy with carboplatin in Korean patients with recurrent ovarian, fallopian tube, or primary peritoneal cancer: a single-institution experience.Substrate Scope of O-Methyltransferase from Streptomyces peucetius for Biosynthesis of Diverse Natural Products Methoxides.Crosstalk between E2F1 and P53 transcription factors in doxorubicin-induced DNA damage: evidence for preventive/protective effects of silymarin.The role of melatonin on chemotherapy-induced reproductive toxicity.Quercetin reverses the doxorubicin resistance of prostate cancer cells by downregulating the expression of c-met.Topoisomerases as anticancer targets.Electrosprayed Myocet-like Liposomes: An Alternative to Traditional Liposome Production.New doxorubicin nanoparticles engineered from calcium-crosslinked carbomer and a microemulsion precursor.Emerging molecular mechanisms in chemotherapy: Ca2+ signaling at the mitochondria-associated endoplasmic reticulum membranes.Targeted delivery of cisplatin to tumor xenografts via the nanoparticle component of nano-diamino-tetrac.Citrate- and Succinate-Modified Carbonate Apatite Nanoparticles with Loaded Doxorubicin Exhibit Potent Anticancer Activity against Breast Cancer Cells.Morphological Analysis of Trafficking and Processing of Anionic and Cationic Liposomes in Cultured Cells.Sex Differences in Cancer: Epidemiology, Genetics and Therapy.Nakai Has Synergetic Effects on Doxorubicin-Induced Apoptosis
P2860
Q36160398-D30E6C0F-77B7-49F1-A883-239BADD02CBFQ37298880-806D441B-1838-401A-91E2-1864F72F33A6Q37302038-AFFE631E-D241-411A-9940-4A7619B67475Q37652873-21DEF5EA-1356-406B-A4DE-85F5D9DAE688Q38410843-46135634-8203-472A-9F75-36F10D09CF84Q38559133-2F4BE710-971E-4D1E-8F57-80C9A62526A1Q38643071-A3D5A6DB-ABE9-4F30-8FF7-450599074AD0Q38708186-2B10D0BF-A4C9-44F9-BB98-9804F7FAFF7EQ38854618-6DF4CDF1-492D-43F3-861D-6BA2EE819E59Q38863577-B1121F88-25AB-4403-A693-B99491C320CDQ38865150-41CCBB3F-1D63-4E7F-9B22-FC657B6B5843Q38872725-3D608DC8-3C39-4EED-A257-C5C3D5434EE1Q42073473-1D0BEB38-1762-46B6-B894-E43FE99A8FD6Q47434368-C4E97834-45C6-4415-A883-7A991A2DEC07Q48099903-134B2FAE-1B02-4A75-A560-D24B320B5DAAQ48249082-5463525C-C4CB-4E89-9F09-316A0396EFE3Q49731583-05C89CCE-6425-4FD9-9B73-F846043469A0Q49832269-5E100F51-C034-4192-8D59-99B4B915F605Q51038520-2E0C0F2B-092F-4551-8333-6B7C72C15CEEQ51158697-1A784E78-41F3-4737-9A74-925522E3CDDFQ51737093-4EE653EB-D194-433C-A41F-B2442CA05B9BQ52800940-40384E6D-8B4E-4EC4-9319-A988D175FA61Q55326759-0291C0DC-428B-4D12-B98C-EC9F568AB42FQ55364642-206FBCB5-3BE7-4CB1-86DF-280DAF03375FQ55406137-ED8840CD-E246-4B1A-876B-8FA7873AD36BQ58805802-99D62D5D-FD9E-48D8-B045-4C2D0B77B273
P2860
An overview of doxorubicin formulations in cancer therapy.
description
2014 nî lūn-bûn
@nan
2014 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
An overview of doxorubicin formulations in cancer therapy.
@ast
An overview of doxorubicin formulations in cancer therapy.
@en
type
label
An overview of doxorubicin formulations in cancer therapy.
@ast
An overview of doxorubicin formulations in cancer therapy.
@en
prefLabel
An overview of doxorubicin formulations in cancer therapy.
@ast
An overview of doxorubicin formulations in cancer therapy.
@en
P356
P1476
An overview of doxorubicin formulations in cancer therapy.
@en
P2093
Sangeeta Rivankar
P304
P356
10.4103/0973-1482.139267
P407
P577
2014-10-01T00:00:00Z